Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Lyell Immunopharma ( (LYEL) ) has shared an announcement.
On December 7, 2025, Lyell Immunopharma presented promising data at the American Society of Hematology Annual Meeting from its clinical trial of ronde-cel, a CAR T-cell product for treating relapsed or refractory large B-cell lymphoma. The trial showed high response rates and manageable safety profiles, with 93% overall response in third-line patients and 83% in second-line patients, indicating potential advancements in treatment options for heavily pre-treated patients.
The most recent analyst rating on (LYEL) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Lyell Immunopharma stock, see the LYEL Stock Forecast page.
Spark’s Take on LYEL Stock
According to Spark, TipRanks’ AI Analyst, LYEL is a Neutral.
Lyell Immunopharma’s overall stock score is primarily influenced by its financial challenges, with significant operational losses and negative cash flow trends. However, strong technical momentum and a strategic corporate event provide positive offsets. The valuation remains a concern due to negative earnings, but the acquisition of LYL273 offers potential future growth opportunities.
To see Spark’s full report on LYEL stock, click here.
More about Lyell Immunopharma
Lyell Immunopharma, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies. The company specializes in chimeric antigen receptor (CAR) T-cell therapies, particularly targeting cancers such as large B-cell lymphoma (LBCL).
Average Trading Volume: 45,697
Technical Sentiment Signal: Buy
Current Market Cap: $535.8M
See more data about LYEL stock on TipRanks’ Stock Analysis page.